Following 14-days AngII infusion period Sphk1−/− mice developed less severe cardiac hypertrophy as compared to WT mice (Heart to body weight ratio for Ang II vs. Sham groups: 5.9 ± 0.22 mg/g vs. 5.5 ± 0.15 mg/g (p = 0.15) in Sphk1−/− mice and 6.8 ± 0.21 mg/g vs. 5.8 ± 0.21 mg/g (p < 0.05) in WT mice). This evidence concerns the gene SPHK1 and cardiac hypertrophy.